Biomedical Research Alliance 3408

1. Teva Pharmaceuticals USA, Inc. $166,989 97 payments
2. Genentech, Inc. $56,314 10 payments
3. Mirati Therapeutics, Inc. $55,091 22 payments
4. Hoffmann-La Roche Limited $7,579 5 payments
5. Takeda Pharmaceuticals U.S.A., Inc. $2,775 3 payments
6. Roche Products Limited $2,145 2 payments

1. A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma $94,273 24 payments
2. Tv50717-Cns-40223 $58,800 64 payments
3. PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $50,418 8 payments
4. A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation $32,918 19 payments
5. A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma $21,352 1 payment
6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder $12,650 5 payments
7. A Phase III Multicenter Randomized Open Label Study Comparing Atezolizumab Anti PD L1 Antibody $9,724 7 payments
8. A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC $5,896 2 payments
9. A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ All) $2,775 3 payments
10. CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $925 1 payment

1. Non-patient care $49,179 19 payments
2. Patient care $5,913 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.